Prometheus Biosciences, Inc., (RXDX): Price and Financial Metrics

Prometheus Biosciences, Inc., (RXDX): $28.20

-0.04 (-0.14%)

POWR Rating

Component Grades













Add RXDX to Watchlist
Sign Up

Industry: Biotech



in industry

RXDX Stock Price Chart Interactive Chart >

Price chart for RXDX

RXDX Price/Volume Stats

Current price $28.20 52-week high $51.96
Prev. close $28.24 52-week low $19.79
Day low $25.79 Volume 1,157,600
Day high $28.59 Avg. volume 349,128
50-day MA $32.20 Dividend yield N/A
200-day MA $32.40 Market Cap 1.11B

Prometheus Biosciences, Inc., (RXDX) Company Bio

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.

RXDX Latest News Stream

Event/Time News Detail
Loading, please wait...

RXDX Latest Social Stream

Loading social stream, please wait...

View Full RXDX Social Stream

Latest RXDX News From Around the Web

Below are the latest news stories about Prometheus Biosciences Inc that investors may wish to consider to help them evaluate RXDX as an investment opportunity.

Ar Asset Management Inc Buys Organon, Prometheus Biosciences Inc, Prometheus Biosciences Inc, ...

Beverly Hills, CA, based Investment company Ar Asset Management Inc (Current Portfolio) buys Organon, Prometheus Biosciences Inc, Prometheus Biosciences Inc, Church & Dwight Co Inc, sells AT&T Inc, Verizon Communications Inc, Marker Therapeutics Inc, Viatris Inc, Vimeo Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Ar Asset Management Inc.

Yahoo | February 7, 2022

Prometheus Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and CEO, will conduct a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022 at

Yahoo | February 7, 2022

5 Biotech Stocks That Are Bucking the Selloff

Biotech investors still like BioCryst, Protagonist, Prometheus Biosciences, Rani, and Emergent BioSolutions. All sported recent double-digit gains despite the sector slump.

Yahoo | January 19, 2022

Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference

- Fast Track Designation granted from U.S. Food and Drug Administration for PRA023 for the treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) - - New patent granted for PRA023 companion diagnostic (CDx) reinforces Prometheus’ precision approach and extends CDx patent coverage into 2040 - - Company to present today at 1:30 PM EST - SAN DIEGO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering

Yahoo | January 12, 2022

Prometheus Biosciences (RXDX) Gets a Buy Rating from Leerink Partners

In a report issued on January 3, Thomas Smith from Leerink Partners maintained a Buy rating on Prometheus Biosciences (RXDX – Research Report). The company's shares closed last Wednesday at $35.74. According to, Smith is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -18.3% and a 21.4% success rate. Smith covers the Healthcare sector, focusing on stocks such as Connect Biopharma Holdings, Madrigal Pharmaceuticals, and Eledon Pharmaceuticals. Currently, the analyst consensus on Prometheus Biosciences is a Strong Buy with an average price target of $45.75.

Christine Brown on TipRanks | January 6, 2022

Read More 'RXDX' Stories Here

RXDX Price Returns

1-mo 7.22%
3-mo -35.23%
6-mo -5.05%
1-year 21.08%
3-year N/A
5-year N/A
YTD -28.68%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7486 seconds.